Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing.

Authors:
Xia Y; Zhang L; He W; Pan H; Fang J and 1 more

Journal:
Cancer Biol Ther

Publication Year: 2023

DOI:
10.1080/15384047.2023.2271212

PMCID:
PMC10761012

PMID:
37906510

Journal Information

Full Title: Cancer Biol Ther

Abbreviation: Cancer Biol Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Therapeutics

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"data availability statement the data that support the findings of this study are openly available in [repository name e g "figshare"] at http://doi org/ [doi] reference number [reference number]. data availability statement the data that support the findings of this study are openly available in [repository name e g "figshare"

Code Sharing
Evidence found in paper:

"Disclosure statement No potential conflict of interest was reported by the author(s)."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025